Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
RXi Pharmaceuticals, Corp.
ClinicalTrials.gov Identifier:
NCT01640912
First received: July 12, 2012
Last updated: September 16, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2014
  Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)